Savani, Saloni, Chennapragada, Suma Sri, Ramphul, Kamleshun, Dandwani, Mehndi, Verma, Renuka, Sanikommu, Sailaja, Pagidipally, Alekhya, Arti, FNU, Kumar, Vijay, Sombans, Shaheen, Ramphul, Yogeshwaree, Mejias, Stephanie G., Dhillon, Balkiranjit Kaur, Lohana, Petras, and Sharma, Shivani
This document is a letter published in the Annals of Hematology that discusses factors associated with inpatient mortality during daunorubicin and cytarabine induction in adults with acute myeloid leukemia (AML). The authors conducted a study using the 2016-2020 National Inpatient Sample (NIS), which is a large database of hospital records in the USA. They found that several patient characteristics and comorbidities were associated with higher or lower chances of inpatient mortality. Factors such as weekend admissions, cirrhosis, obesity, chronic kidney disease, and age over 60 were associated with higher mortality, while being Hispanic, having a larger bed size, and having diabetes or hypertension were associated with lower mortality. The study also found that complications such as septicemia, acute kidney injury, and cardiogenic shock were common during induction therapy and increased mortality. [Extracted from the article]